Contact

Paxman publishes newsletter on AMA resolutions to advocate for universal insurance coverage of scalp cooling

Today, Paxman publishes the June issue of its newsletter aimed at shareholders, investors and other interested parties.

This month’s issue highlights that the American Medical Association (AMA) resolved to advocate for and seek through legislation and/or regulation, universal insurance coverage for scalp cooling therapy at the annual meeting for its principal policy-making body House of Delegates (HOD). At the meeting, AMA also resolved to work with consumer and advocacy groups to challenge insurers on medical necessity denials for scalp cooling therapy and encourage appeals of such decisions.

The newsletter also includes information on that Paxman celebrated five successful years in the US at the recent ASCO annual meeting, this month’s orders and installations in the US, the UK and rest of the world including 10 systems to Japan, that Paxman won the National Medilink UK Award for Outstanding Achievement, and the fourth episode of the Changing the Face of Cancer podcast where the chemotherapy side effect CIPN is discussed.

To read the newsletter and subscribe for upcoming issues, follow this link:

https://bit.ly/paxjun22en

Paxman’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on Paxman’s website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

What we do
Paxman are world leaders in chemotherapy side effect management on an ambitious journey to change the face of cancer through cryotherapy-based treatments. The Paxman mission is to democratise access to scalp cooling globally.
Learn more →
Financial Information
Read the latest Paxman financial reports. In these comprehensive documents, you will find a detailed overview of our financial performance, key milestones, and a strategic outlook for the future. Reports are published quarterly and annually.
Read reports  →
Investing in Paxman
Paxman has treated 100,000+ patients and installed 5,000+ systems in more than 65 countries worldwide. We are helping to manage the trauma of chemotherapy hair loss. By investing in Paxman, you're not just supporting a company; you're joining us in changing the face of cancer.
Visit the Investor Centre →
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram